Corona Vaccine

Can Bharat Biotech Develop Corona Vaccine for India???

Coronavirus

With a vision to offer affordable, safe and effective healthcare solutions to combat the corona pandemic, Bharat Biotech is assigned the task to develop the corona vaccine for India by ICMR.

The Indian Council of Medical Research (ICMR) handshake with Bharat Biotech International Limited (BBIL) to develop an indigenous vaccine for coronavirus. The team has been authorized to use the virus strain preserved at ICMR’s National Institute of Virology (NIV), Pune. As on date, Bharat Biotech has over 160 patents.

COVID Vaccine

As informed by Union Minister of Health Harsh Vardhan, India has already recorded 59,662 corona cases and 1,981 deaths to date. In the last 24 hours, 3,320 new confirmed cases have been reported. India is experiencing a fatality rate of 3.3% and recovery rate is 29.9%.

Also Read: Good News for World: Coronavirus Vaccine Trial Successful on 14 People

About Bharat Biotech International Limited (BBIL)?

1996 Dr. Krishna M. Ella & Mrs. Suchitra Ella started Bharat Biotech in Genome Valley, Hyderabad. It was the first biotech company in the biotechnology park of Hyderabad. Both of them returned from the US to start the organization. The main motto was to create innovative vaccines and bio-therapeutics. BBIL has given professionally experts and bright scientists to India in the over last two decades. To date the biotech giant has created path-breaking vaccines.

Also Read: COVID-19: What is Herd Immunity? Can it Work Against Coronavirus?

Can Bharat Biotech Develop the Corona Vaccine????

Lately, ICMR has assigned Bharat Biotech the task being chased by all the biotech giants of the world. In order to look at the capabilities of Bharat Biotech, we should first analyze what Bharat Biotech has achieved so far.

Corona Vaccine

1998

Dr. A.P.J Abdul Kalam launched Revac-B+®—world’s first Cesium Chloride free Hepatitis B vaccine created by Bharat Biotech.

1999

They expanded the capacity to make 100 million doses of Revac-B+® annually to become the largest manufacturers of Hepatitis B vaccines in the world.

2001

Chandrababu Naidu,  Chief Minister of Andhra Pradesh launched BIOGIT®—India’s first probiotic yeast and Bharat Biotech’s first bio-therapeutic product.

2002

BBIL became the first Indian company to receive two grants from the Bill & Melinda Gates Foundation through Program for Appropriate Technology in Health (PATH) to develop new vaccines against Malaria and Rotavirus.

2003

Bharat Biotech felicitated Dr. John B. Robbins—the father of polysaccharide vaccines for his tremendous contribution to the world of vaccines.

2004

Bharat Biotech pioneered REGEN-D®—India’s first recombinant human epidermal growth factors for Degree I & Degree II burns, skin grafts, and diabetic foot ulcers. BBIL simultaneously launched its 2nd bio-therapeutic product, ZELECT®.

2005

Announced a manufacturing and marketing agreement with Cambridge-based Acambis, plc., for developing the Japanese Encephalitis vaccine—a neglected disease.

2006

Dr. Julie Gerberding, Director, Centre for Disease Control and Prevention (CDC) launched the chromatographically purified Vero cell rabies vaccine, named INDIRAB® (then Rabirix®).

2007

Launched BioHib®—India’s first indigenously developed and manufactured Haemophilus Influenza Type B (Hib) vaccine.

2008

Dr. Manmohan Singh, former Prime Minister of India, presented FICCI Award to Bharat Biotech by the Federation of Indian Chambers of Commerce and Industry for “Excellence in Science, Technology and Technological Innovation”.

2009

Senior General Mr. Than Shwe, Chairman, State Peace & Development Council, Union of Myanmar launched Comvac 5 PFS® (Pre-filled syringes)—Pentavalent Combination vaccine—Bharat Biotech’s best-selling product.

2010

Launched HNVAC® – India’s first cell culture-based H1N1 (Human Inactivated Influenza A virus) Swine flu Vaccine.

Corona Vaccine

2011

The co-chair of the Bill & Melinda Gates Foundation and Chairman of Microsoft, met Dr. Krishna Ella, CMD of Bharat Biotech, regarding the development of Rotavac—Bharat Biotech’s affordable diarrheal vaccine.

2012

Bharat Biotech & University of Maryland collaboratively received USD 4 Million ‘Strategic Translation Award’ from the Wellcome Trust for clinical development of a new life-saving conjugate vaccine for Invasive Non-Typhoidal Salmonella (iNTS).

2013

Launched Typbar TCV®—the world’s 1st clinically proven conjugate Typhoid vaccine.

2014

Launched JENVAC®—a safe and highly effective vaccine that protects against all the known strains of Japanese encephalitis.

2015

Shri. Narendra Modi, Prime Minister of India launched ROTAVAC—rotavirus vaccine. It became the first vaccine under the “Make-in-India’ initiative.

2016

Bharat Biotech became the first company in the world to file a global patent for the Zika vaccine.

2017

TYPBAR-TCV demonstrated 87% efficacy in the world’s first Typhoid Human Challenge study carried out at Oxford University.

2018

WHO prequalified TYPBAR-TCV and ROTAVAC vaccines.

Conclusion

Thus, Bharat Biotech seems to be capable of developing the Corona vaccine (COVID-19 vaccine) for India in minimal time to safeguard the India and rest of the world. All the biotech giants across the world are in a hurry to claim the crown. At this stage, even if Bharat Biotech would develop the vaccine with supersonic speed, the tests, medical and government formalities would enlengthen the time.  In this case, we would in the condition to import the vaccine from other countries viz. Italy, Israel, USA, China and the UK, who are at a far better stage of development of the corona vaccine than India.

Source: https://www.bharatbiotech.com/

Please follow and like us:

2 thoughts on “Can Bharat Biotech Develop Corona Vaccine for India???

  1. I am glad that I found this article well documented and very informative.

    I want to share how I treated Yeast and Candida Infection, maybe it will be useful to someone.
    Thank you and keep going, you do a great job!!

Leave a Reply

Your email address will not be published. Required fields are marked *